Cereno Scientific AB Class B (4A1) Stock Statistics & Valuation Metrics
Total Valuation
Cereno Scientific AB Class B has a market cap or net worth of EUR 59.09M. The enterprise value is EUR 154.23M.
- Market Cap
- EUR 59.09M
- Enterprise Value
- EUR 154.23M
Share Statistics
Cereno Scientific AB Class B has 323,129,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 323,129,800
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Cereno Scientific AB Class B’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
- Return on Equity (ROE)
- ―
- Return on Assets (ROA)
- ―
- Return on Invested Capital (ROIC)
- ―
- Return on Capital Employed (ROCE)
- ―
- Revenue Per Employee
- ―
- Profits Per Employee
- -4.60M
- Employee Count
- 1
- Asset Turnover
- ―
- Inventory Turnover
- ―
Income Statement
In the last 12 months, Cereno Scientific AB Class B had revenue of ― and earned -4.60M in profits. Earnings per share was ―.
- Revenue
- ―
- Gross Profit
- 9.21M
- Operating Income
- -4.59M
- Pretax Income
- ―
- Net Income
- -4.60M
- EBITDA
- -4.59M
- Earnings Per Share (EPS)
- ―
Stock Price Statistics
- Beta
- 0.54
- 52-Week Price Change
- -74.58%
- 50-Day Moving Average
- 0.35
- 200-Day Moving Average
- 0.47
- Relative Strength Index (RSI)
- 27.42
- Average Volume (3m)
- 9,309
Important Dates
Cereno Scientific AB Class B upcoming earnings date is Nov 04, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 26, 2026
- Next Earnings Date
- Nov 04, 2026
- Ex-Dividend Date
- ―
Balance Sheet
Cereno Scientific AB Class B has ― in cash and marketable securities with EUR 9.76M in debt, giving a net cash position of ― billion.
- Cash & Marketable Securities
- ―
- Total Debt
- EUR 9.76M
- Net Cash
- ―
- Net Cash Per Share
- ―
- Tangible Book Value Per Share
- ―
Analyst Forecast
The average price target for Cereno Scientific AB Class B is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -6.70%
